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Predicting Antibiotic Resistance in Urinary Tract Infection Patients
with Prior Urine Cultures
Yaakov Dickstein,a* Yuval Geffen,b Steen Andreassen,c Leonard Leibovici,d Mical Paula
Division of Infectious Diseases, Rambam Healthcare Campus, Haifa, Israela; Medical Microbiology Laboratory, Rambam Healthcare Campus, Haifa, Israelb; Center for
Model-Based Medical Decision Support, Aalborg University, Aalborg, Denmarkc; Medicine E, Rabin Medical Center, Beilinson Hospital, Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israeld
To improve antibiotic prescribing, we sought to establish the probability of a resistant organism in urine culture given a previ-
ous resistant culture in a setting endemic for multidrug-resistant (MDR) organisms. We performed a retrospective analysis of
inpatients with paired positive urine cultures. We focused on ciprofloxacin-resistant (cipror) Gram-negative bacteria, extended-
spectrum-beta-lactamase (ESBL)-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and carbap-
enem-resistant nonfermenters (CRNF). Comparisons were made between the frequency of each resistance phenotype following a
previous culture with the same phenotype and the overall frequency of that phenotype, and odds ratios (ORs) were calculated.
We performed a regression to assess the effects of other variables on the likelihood of a repeat resistant culture. A total of 4,409
patients (52.5% women; median age, 70 years) with 19,546 paired positive urine cultures were analyzed. The frequencies of cipror
bacteria, ESBL-producing Enterobacteriaceae, CRE, and CRNF among all cultures were 47.7%, 30.6%, 1.7%, and 2.6%, respec-
tively. ORs for repeated resistance phenotypes were 1.87, 3.19, 48.25, and 19.02 for cipror bacteria, ESBL-producing Enterobacte-
riaceae, CRE, and CRNF, respectively (P < 0.001 for all). At 1 month, the frequencies of repeated resistance phenotypes were
77.4%, 66.4%, 57.1%, and 33.3% for cipror bacteria, ESBL-producing Enterobacteriaceae, CRE, and CRNF, respectively. Increas-
ing time between cultures and the presence of an intervening nonresistant culture significantly reduced the chances of a repeat
resistant culture. Associations were statistically significant over the duration of follow-up (60 months) for CRE and for up to 6
months for all other pathogens. Knowledge of microbiology results in the six preceding months may assist with antibiotic stew-
ardship and improve the appropriateness of empirical treatment for urinary tract infections (UTIs).
Appropriate empirical treatment of urinary tract infections(UTIs) is important for successful treatment and prevention
of complications. However, with the increasing prevalence of an-
tibiotic-resistant urinary pathogens, the selection of an appropri-
ate empirical agent is increasingly difficult. This is reflected in
2010 clinical practice guidelines which recommend using nitrofu-
rantoin as a first-line agent in place of cotrimoxazole, owing to a
rise in the occurrence of organisms resistant to the latter (1, 2).
Resistance to other antimicrobials used in the treatment of UTIs,
particularly fluoroquinolones, is also increasing, as is the preva-
lence of extended-spectrum-beta-lactamase (ESBL)-producing
Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas
aeruginosa (3–5).
The problem is particularly prominent in the hospital setting,
where UTIs can present as severe infections and MDR organisms
are frequent. Although inappropriate initial treatment of cystitis
seldom leads to significant morbidity or mortality, failing to treat
patients with severe infections may have more serious conse-
quences. A study of hospitalized patients with UTIs due to ESBL-
producing pathogens found that inappropriate empirical therapy
was associated with longer treatments and lengths of hospital stay
as well as higher costs (6). Among bacteremic patients, inappro-
priate empirical treatment is associated with higher mortality (7).
One technique commonly practiced by clinicians is basing therapy
on the results of previous urine cultures. Previous cultures are
frequently available in the health care setting, and with the com-
puterization of health care records, such information can easily be
obtained at the point of care. However, to use this information,
data are needed on the predictive value of previous cultures strat-
ified by the time elapsed prior to the current infection.
Given the challenge of determining a priori which patients will
ultimately have infection due to a resistant organism, we sought to
determine the value of a previous culture with a resistant uro-
pathogen for predicting growth of resistant bacteria in a subse-
quent culture among hospitalized patients in a setting where MDR
organisms are endemic.
MATERIALS AND METHODS
We performed a retrospective study of all patients with repeat positive
urine cultures at Rambam Health Care Campus, a 900-bed primary and
tertiary hospital in northern Israel, from 2011 to 2015. All the urine cul-
tures were taken for a clinical indication (suspicion of infection). We
included patients with polymicrobial cultures and cultures yielding
growth of Gram-positive bacteria and yeasts; multiple cultures taken on
the same date were included and assessed similarly to polymicrobial cul-
tures. Negative (sterile) cultures were excluded from the analysis. Cultures
were analyzed per patient based on the presence or absence of resistance
profiles on a given date, regardless of the number of organisms present.
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Patients could be considered positive for more than one resistance profile
simultaneously on a given date.
Data were obtained from the electronic registry of the hospital, which
records demographic, administrative, and microbiological data. Patients
were identified through the microbiology reports. Antibiotic susceptibil-
ity testing was performed using a Vitek 2.0 system and Etest based on CLSI
criteria. ESBL-producing Enterobacteriaceae were defined as Enterobacte-
riaceae resistant to all third-generation cephalosporins, including ceftazi-
dime.
Cultures were assessed for the presence of any ciprofloxacin-resistant
(cipror) Gram-negative bacteria, ESBL-producing Enterobacteriaceae,
carbapenem-resistant Enterobacteriaceae (CRE), or carbapenem-resistant
nonfermenters (CRNF; including Pseudomonas and Acinetobacter spe-
cies). In the first analysis, we compared the presence of the resistance
phenotype in the repeat urine culture and the immediately previous pos-
itive culture. In the second analysis, we compared resistances in urine
cultures with those in any previous positive culture. The chance of a sub-
sequent culture being positive for the same phenotype of resistance as the
previous culture was determined. We compared it to the prevalence of
resistance in our population (for the same phenotype) among all repeat
urine cultures by using the 2 test. Odds ratios (ORs) with 95% confidence
intervals (CIs) and other test characteristics (sensitivity, specificity, posi-
tive predictive value [PPV], and negative predictive value [NPV]) are
reported for a repeat resistant organism given a known prior resistant
organism compared to the baseline prevalence of resistance. Additionally,
we analyzed the likelihood of an antibiotic-sensitive organism (i.e., no
cipror bacteria, ESBL-producing Enterobacteriaceae, CRE, or CRNF)
given prior cultures with only sensitive organisms. A multivariate analysis
was performed to determine risk factors for repeated growth of resistant
organisms in patients with a previous resistant organism. A sensitivity
analysis was performed by excluding cultures taken within 14 days of one
another. All analyses were performed using SPSS 23 and VassarStats.
RESULTS
A total of 4,409 patients with 19,546 paired positive urine cultures
were analyzed from a total of 26,692 positive urine cultures during
the study period. About half (52.5%) of the patients were female,
with a median (interquartile range [IQR]) age of 70 (55 to 81)
years. The department of admission at the time when the final
culture was taken was the emergency room (ER) for 15.0% of
patients, medicine for 36.6%, surgery for 46.2%, and intensive
care unit (ICU) for 2.1%. The overall frequencies of cipror bacte-
ria, ESBL-producing Enterobacteriaceae, CRE, and CRNF in the
cultures included in the analysis were 49.9%, 26.5%, 1.7%, and
2.8%, respectively.
All four resistance phenotypes were significantly more fre-
quent following a previous culture with the same phenotype, re-
gardless of organism identity. For patients whose last urine culture
grew a resistant organism, the ORs for a culture positive for cipror
bacteria, ESBL-producing Enterobacteriaceae, CRE, and CRNF
were 1.87 (95% CI, 1.74 to 2.01), 3.19 (95% CI, 2.91 to 3.49), 48.25
(95% CI, 34.13 to 68.22), and 19.02 (95% CI, 14.38 to 25.17),
respectively (P  0.001 for all), for the overall follow-up duration,
with a median (IQR) of 26 (7 to 104) days between the immedi-
ately previous culture and the final urine culture. For patients with
any previously positive culture with a resistance phenotype, the
ORs were 1.64 (95% CI, 1.54 to 1.75), 2.42 (95% CI, 2.23 to 2.61),
31.74 (95% CI, 23.66 to 42.58), and 9.82 (95% CI, 7.80 to 12.36),
respectively (P  0.001 for all), with a median (IQR) of 34 (9 to
122) days between cultures for cipror bacteria, 45 (11 to 156) days
for ESBL-producing Enterobacteriaceae, 55 (11 to 190) days for
CRE, and 49 (14 to 189) days for CRNF. Except for ciprofloxacin
resistance, specificity and NPVs were high, while all other diag-
nostic performance values were low (Table 1).
Excluding cultures taken within 14 days of one another yielded
similar results. For patients whose last urine culture grew a resis-
tant organism, the ORs for a culture positive for cipror bacteria,
ESBL-producing Enterobacteriaceae, CRE, and CRNF were 1.86
(95% CI, 1.70 to 2.05), 3.30 (95% CI, 2.94 to 3.71), 41.41 (95% CI,
26.17 to 65.53), and 12.64 (95% CI, 8.32 to 19.22), respectively
(P  0.001 for all). For patients with any previously positive cul-
ture with a resistance phenotype, the ORs were 1.94 (95% CI, 1.79
to 2.10), 2.78 (95% CI, 2.54 to 3.05), 31.67 (95% CI, 22.24 to
45.11), and 7.30 (95% CI, 5.41 to 9.86), respectively (P  0.001 for
all).
For patients whose previous urine culture grew a sensitive
organism, i.e., lacking all resistance phenotypes assessed, the
OR for a sensitive organism in the next culture was 3.37 (95%
CI, 3.10 to 3.67) (P  0.001). For patients in whom all previous
cultures grew sensitive organisms, the value was 3.55 (95% CI,
3.26 to 3.86) (P  0.001). The sensitivity, specificity, PPV, and
NPV were low (Table 1).
As shown in Fig. 1, the frequency of a repeat culture positive for
cipror bacteria or ESBL-producing Enterobacteriaceae increased in
the first 2 weeks after the previous culture and thereafter de-
creased, whereas the frequencies of repeat CRE and CRNF cul-
tures decreased continuously with time from the initial culture.
TABLE 1 Test characteristics for effects of previous resistance profiles
Culture group and resistance
phenotype
Median (95% CI)
Sensitivity Specificity Positive predictive value Negative predictive value
Immediately previous culture
cipror 0.38 (0.37–0.39) 0.76 (0.75–0.77) 0.68 (0.66–0.69) 0.47 (0.46–0.48)
ESBL producer 0.33 (0.31–0.34) 0.87 (0.86–0.88) 0.56 (0.54–0.58) 0.72 (0.71–0.72)
CRE 0.29 (0.24–0.35) 0.99 (0.99–0.99) 0.48 (0.40–0.56) 0.98 (0.98–0.98)
CRNF 0.24 (0.20–0.29) 0.98 (0.98–0.99) 0.37 (0.31–0.43) 0.97 (0.97–0.97)
Sensitive to all antibiotics tested 0.66 (0.64–0.67) 0.64 (0.62–0.65) 0.58 (0.57–0.60) 0.71 (0.69–0.72)
Any previous culture
cipror 0.42 (0.41–0.43) 0.69 (0.68–0.70) 0.65 (0.63–0.66) 0.47 (0.46–0.48)
ESBL producer 0.38 (0.37–0.40) 0.80 (0.79–0.80) 0.49 (0.47–0.51) 0.72 (0.71–0.72)
CRE 0.34 (0.29–0.40) 0.98 (0.98–0.99) 0.38 (0.32–0.44) 0.98 (0.98–0.98)
CRNF 0.30 (0.26–0.35) 0.96 (0.95–0.96) 0.23 (0.20–0.27) 0.97 (0.97–0.97)
Sensitive to all antibiotics tested 0.54 (0.53–0.56) 0.75 (0.74–0.76) 0.62 (0.61–0.64) 0.68 (0.67–0.69)
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The initially lower frequencies of cipror bacteria and ESBL-pro-
ducing Enterobacteriaceae seen in cultures taken within 7 days of
the previous culture reflected the predominance of cultures taken
during the same admission; among repeat cultures taken on new
admissions, the rates of cipror bacteria and ESBL-producing En-
terobacteriaceae were 72.1% and 63.0% (versus 54.6% and 40.5%
in cultures from the same admission), respectively. The frequen-
cies of all four resistance phenotypes decreased steadily starting 2
weeks following the initial culture. Among cultures taken approx-
imately 1 and 3 months following previous cultures with a resis-
tance phenotype, the frequencies of cultures with the same phe-
notype were 77.4%, 66.4%, 57.1%, and 33.3% at 1 month and
73.8%, 47.1%, 33.3%, and 0% at 3 months for cipror bacteria,
ESBL-producing Enterobacteriaceae, CRE, and CRNF, respec-
tively.
Multivariate analyses were performed for each of the resistance
phenotypes (Table 2). Increasing time between cultures and the
presence of at least one intervening culture negative for the resis-
tance phenotype decreased the risk of a subsequent culture being
positive for a resistant organism for all four resistance phenotypes.
For cipror bacteria, increasing age and male gender were associ-
ated with increased risk; for ESBL-producing Enterobacteriaceae,
male gender and emergency room admission increased risk; for
CRE, no other factors significantly affected risk; and for CRNF,
increasing age decreased risk. Results were similar for exclusion of
repeat cultures performed within 14 days of each other, although
increasing time was not significantly associated with a drop in the
risk of CRE, age was not associated with the risk of CRNF, and
hospital department was positively associated with the risk of
cipror bacteria (data not shown).
DISCUSSION
We analyzed whether the presence of a resistant organism in a
previous urine culture predicts the growth of an organism with the
same resistance phenotype in a subsequent urine culture. In a
population with high frequencies of resistance to ciprofloxacin
and extended-spectrum beta-lactams, we found that a previous
culture with a resistant organism was predictive of a repeat resis-
tant organism, with the highest risk if the previous organism was
carbapenem resistant. Conversely, previous cultures with sensi-
tive organisms were predictive of repeat culture of an antibiotic-
sensitive organism. The existence of at least one intervening cul-
ture negative for organisms with a resistance phenotype as well as
increasing time from the original culture significantly reduced the
chances of a repeat resistant organism. The association remained
significant at 6 months for cipror bacteria, ESBL-producing Enter-
obacteriaceae, and CRNF, whereas the association between CRE
and time between cultures was weak, indicating that CRE in urine
persist for prolonged durations; in the sensitivity analysis exclud-
ing 14-day repeat cultures, the time between cultures was not a
significant modifier of the risk for recurrent CRE infection. The
effects of other factors on risk, including age, gender, and depart-
ment of hospitalization, varied between resistance phenotypes.
In general, the association between cultures decreased with
time. However, we observed increasing associations for frequen-
cies of cipror bacteria and ESBL-producing Enterobacteriaceae in
cultures taken within 1 week of previous cultures. This reflected
the rates of these phenotypes in cultures which were taken within
the same hospitalization and which, unsurprisingly, made up the
majority of repeated cultures in this short period. This may be due
to the fact that in the hospital, the natural history of colonization/
persistence is disturbed by antibiotic treatment, which masks the
association between previous and recurrent resistances.
A recent study examining the added value of previous cultures
found that they predicted both bacterial species and antibiogram,
and a subanalysis of susceptibility to ciprofloxacin found that a
previous culture with a ciprofloxacin-susceptible pathogen was
predictive of sensitivity to the antibiotic in a subsequent culture
(8). That study consisted primarily of cultures taken from outpa-
tients with relatively low rates of antibiotic resistance; the number
of cultures analyzed for antibiotic susceptibility was similar to that
in the present work. In comparison, our analysis was performed
on a mostly hospital-based population with widespread resistance
and provides information on several resistance phenotypes. We
chose to analyze bacterial groups rather than specific bacterial
species (although a separation was maintained between the Enter-
obacteriaceae and P. aeruginosa/Acinetobacter spp.), focusing on
susceptibility patterns of resistant rather than sensitive organisms,
since this information is more helpful to antibiotic prescribers.
While the previous study benefited from having information on
antibiotic treatment in the interim since the previous culture,
which is information we lacked, there were no details provided on
said treatment, including whether it covered the organism in the
prior culture.
FIG 1 (a) Frequencies of cipror bacteria, ESBL-producing Enterobacteriaceae,
CRE, and CRNF after positive immediately previous culture. (b) Frequen-
cies of cipror bacteria, ESBL-producing Enterobacteriaceae, CRE, and CRNF
after any positive previous culture. Cipro-R, ciprofloxacin-resistant bacte-
ria; CRE, carbapenem-resistant Enterobacteriaceae; CRNF, carbapenem-re-
sistant nonfermenters; ESBL, extended-spectrum-beta-lactamase-produc-
ing Enterobacteriaceae.
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A second retrospective study assessing methods to improve the
accuracy of empirical antibiotics among patients who had UTIs
with multidrug-resistant organisms found that employing an an-
timicrobial concordant with prior culture results, where applica-
ble, increased the likelihood of appropriate therapy 7-fold (9).
That study had access to information on prior antibiotic treat-
ment and its appropriateness as well as the virtue of simplicity and
easy introduction of its findings into clinical practice. However,
the analysis involved a small number of cultures (126), which may
explain why there was no significant association between time
from initial culture and likelihood of accurate therapy; addition-
ally, 90% of the patients were male, which fails to represent the
typical cohort for UTIs. MDR was defined as resistance to three or
more classes of antibiotics, which would fail to include ESBL-
producing Enterobacteriaceae.
Prescription of appropriate empirical antibiotic treatment ne-
cessitates consideration of the probability of bacterial infection, its
source, and the bacterial epidemiology of that infection source
(types of bacteria and resistance patterns) given the circumstances
of infection acquisition (degree of exposure to the health care
setting). The knowledge gained from previous cultures can also
contribute to these baseline probabilities. We quantified this con-
tribution for UTIs. It is likely that other cultures can contribute
similarly to the process of selecting empirical antibiotics (e.g., us-
ing results of previous sputum cultures to prescribe antibiotics for
pneumonia). It is also likely that the association differs by type of
previous culture and the current infection, since the natural his-
tories of colonization in the urinary, gastrointestinal, and respira-
tory tracts differ. It is difficult to compute this matrix of probabil-
ities in clinical practice and to incorporate ORs for previous
cultures. Sensitivity, specificity, PPV, and NPV were mostly un-
helpful, with none of the PPVs exceeding 70%. Only a lack of


















cipror Age 0.033 0.019 1.004 (1.001–1.007) 0.009 0.002 1.006 (1.002–1.010)
Male gender 0.001 0.001 1.288 (1.151–1.440) 0.001 0.001 1.274 (1.108–1.464)
Time between cultures 0.014 0.016 1.000 (0.999–1.000) 0.001 0.001 0.999 (0.999–1.000)
Intervening cultures without
cipror
0.001 0.001 0.565 (0.496–0.645) 0.001 0.001 0.455 (0.392–0.528)
ER 0.024 0.508 0.610
Surgery 0.009 0.406 0.001 0.292
ICU 0.017 0.115 0.019 0.008 0.397 (0.201–0.783)
Medicine 0.001 0.283 0.001 0.022 0.796 (0.655–0.968)
ESBL producer Age 0.011 0.069 0.008 0.062
Male gender 0.001 0.001 1.386 (1.206–1.593) 0.003 0.005 1.271 (1.075–1.501)
Time between cultures 0.013 0.001 0.999 (0.999–1.000) 0.001 0.001 0.999 (0.999–0.999)
Intervening cultures without
ESBL producer
0.001 0.001 0.449 (0.385–0.524) 0.001 0.001 0.354 (0.298–0.420)
ER 0.001 0.001 1.552 (1.264–1.905) 0.001 0.018 1.314 (1.048–1.648)
Surgery 0.017 0.663 0.019 0.957
ICU 0.215 0.606
Medicine 0.487 0.900
CRE Age 0.222 0.904
Male gender 0.662 0.072
Time between cultures 0.001 0.044 0.999 (0.997–1.000) 0.001 0.059
Intervening cultures without
CRE





CRNF Age 0.001 0.001 0.978 (0.967–0.990) 0.359
Male gender 0.548 0.718
Time between cultures 0.001 0.001 0.996 (0.994–0.998) 0.001 0.032 0.998 (0.996–1.000)
Intervening cultures without
CRNF
0.001 0.001 0.287 (0.175–0.471) 0.001 0.001 0.333 (0.182–0.609)
ER 0.359 0.935
Surgery 0.025 0.297 0.027 0.243
ICU 0.231 1.000
Medicine 0.019 0.333 0.020 0.235
a Odds ratios for the time between cultures are values per day. “ER,” “surgery,” “ICU,” and “medicine” indicate patient locations at the times of second culture.
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carbapenem resistance was predictive of no such resistance in sub-
sequent cultures with a high degree of certainty. Computerized
decision support systems might make better use of baseline prob-
abilities of infection and susceptibilities by accounting for quan-
titative factors, such as the time since previous culture (10).
Our study has several advantages. By including all urine cul-
tures, including polymicrobial cultures, we reflected a “real-
world” setting in which physicians have to deal with multiple cul-
ture results and it is not always possible to ascertain if previous
cultures were taken properly. By analyzing different resistance
phenotypes independently, we showed differences in the timing
and risk factors for repeat resistant organisms, presumably reflect-
ing differing baseline prevalences of these resistance patterns. Our
main limitation is that we had no means of determining if patients
had received antibiotics, particularly covering antibiotics, in the
interval since their previous culture. However, it is not always
possible to obtain such information from patients in clinical set-
tings. A previous study showed that use of any antibiotic (regard-
less of coverage of the initial isolate) in the interval between urine
cultures decreased the rates of concordance between cultures, but
the effect was still significant after antibiotic treatment, and the
trends with time were conserved (8). Our sensitivity analysis ex-
cluding repeat cultures taken within 14 days of the initial culture
showed results similar to those of the main analysis. Further stud-
ies should establish the association with covering and noncovering
intervening antibiotics. We also lacked information on clinical
symptoms, the presence of urinary catheters and other devices
(which might explain the continued persistence of CRE), and cul-
tures taken outside our hospital (11). While this is a serious limi-
tation to answering questions on the mechanism of resistance for-
mation, the present study was an effort to provide a pragmatic
solution to the bedside clinician, who may also lack information
regarding the circumstances under which previous cultures were
taken, prior antibiotics used, and cultures taken outside his or her
hospital system. A third potential disadvantage was that our anal-
ysis did not include negative culture results. Since in our institu-
tion urine cultures are frequently taken without suspicion of UTI,
inclusion of the culture-negative samples would have biased the
ORs toward the null. Thus, our results apply to patients with clin-
ically suspected UTI for whom empirical antibiotics are consid-
ered necessary. A final limitation was the possibility that analyzing
paired cultures biased the study toward a patient population with
an increased frequency of antibiotic resistance. However, such a
bias is presumably true for any cohort with repeated cultures and
does not affect the predictive value of the earlier culture for resis-
tant organisms in subsequent cultures. Furthermore, the use of
the same methodology as that used in a previous study allows for
better comparison of our findings (8).
In conclusion, in a location with high rates of antibiotic resis-
tance and without information on antibiotic therapy and other
potential confounders, a urine culture positive for a resistant
Gram-negative organism was predictive of a subsequent culture
with the same resistance phenotype. Physicians should prescribe
empirical antibiotics for patients with severe urinary tract infec-
tions that cover resistant organisms if these were identified in a
previous urine culture, particularly when there are no intervening
negative cultures and the time since the preceding culture is less
than 6 months. The protective nature of intervening negative cul-
tures is an interesting finding inviting further study.
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